Skip to main content
OpenTrials
Completed

NCT Number: NCT02165618

Rationalisation of Polypharmacy by the Geriatric Consultation Team

Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments.

(* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Iatrogenic Disease Disease Attributes Frailty Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

75 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospitals Leuven

Leuven, Flemish Brabant, 3000, Belgium

About this study

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events .

The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Admitted to a non-geriatric ward
  • 75 years or older
  • Dutch speaking
  • Consultation by the GCT

Exclusion criteria

  • End-of-life
  • No drugs on admission

Treatment and study plan

Medication review, based on but not limited to the RASP list

Other

Systematic approach:

  • Medication reconciliation
  • Applying the RASP list
  • Expert review (not based on the RASP list)
  • Multidisciplinary discussion

Other names: RASP, RASP list, Systematic medication review

Primary outcomes

  1. Number of medication-related recommendations by the geriatric consultation team.

    Time frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

Secondary outcomes

  1. Number of potentially inappropriate drugs at discharge, as identified by the RASP list.

    Time frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

  2. Number of drugs at discharge, relative to the drugs on admission.

    Time frame: The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

  3. Acceptance rate of the GCT interventions by the treating physician.

    Time frame: Up to 72 hours after the GCT had given its recommendations.

Sponsors and collaborators

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Other

Registry information

Official study title

Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study

Acronym: RASP-GCT

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Jun 17, 2014
Registry last updated
Jun 17, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.